Asia
With a priority review voucher in hand, Teva is expecting the FDA to rule on its new migraine treatment fremanezumab by June.
Zhejiang Medicine has terminated its Phase III oncology trial for oral forms of prochloridine mesylate to treat AML due to a lack of efficacy.
Biotechnology major BioCon is likely to take its group entity Biocon Biologics public and is expected to raise about $500M.
Another attempt at developing a treatment for Alzheimer’s has hit a wall.
The parent company of JSR Life Sciences snapped up CRO Crown Bioscience International for $400M, the company announced this morning.
Should you invest the way billionaire investors do?
The Israeli government isn’t considering punitive measures against debt-strapped Teva over its plan to fire a quarter of its Israeli work force, according to an official close to Prime Minister Benjamin Netanyahu.
Chiome Bioscience says it announces termination of candidate antibody related joint research contract, which was signed between the co and Chugai Pharma, as the contract has expired on Dec. 31
Clover Biopharmaceuticals, a Chengdu biotech startup, completed a $9.5M Series A financing led by Tianhe Life Sciences Venture Fund.
Teva pulled the trigger on a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.
PRESS RELEASES